Showing 2,041 - 2,060 results of 3,304 for search '"clinical trial"', query time: 0.09s Refine Results
  1. 2041

    Current Pharmacological Management of Gastroesophageal Reflux Disease by Yao-Kuang Wang, Wen-Hung Hsu, Sophie S. W. Wang, Chien-Yu Lu, Fu-Chen Kuo, Yu-Chung Su, Sheau-Fang Yang, Chiao-Yun Chen, Deng-Chyang Wu, Chao-Hung Kuo

    Published 2013-01-01
    “…Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment.…”
    Get full text
    Article
  2. 2042

    Multitargeted Effects of Vitexin and Isovitexin on Diabetes Mellitus and Its Complications by Ibrahim Luru Abdulai, Samuel Kojo Kwofie, Winfred Seth Gbewonyo, Daniel Boison, Joshua Buer Puplampu, Michael Buenor Adinortey

    Published 2021-01-01
    “…This is expected to provide a deeper understanding of its actions and also serve as a catapult for clinical trials and application research.…”
    Get full text
    Article
  3. 2043
  4. 2044

    Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies by Aarat Patel, Georgia Seely, Rohit Aggarwal

    Published 2016-01-01
    “…Overall, these results are encouraging and suggest that randomized, controlled clinical trials applying RCI to dermatomyositis and polymyositis are warranted.…”
    Get full text
    Article
  5. 2045

    Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

    Published 2015-01-01
    “…With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+ regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.…”
    Get full text
    Article
  6. 2046

    Repurposing radiosensitising medicines for radiotherapy: an overview by Geoff S Higgins, Jie Man Low, Gonzalo Rodriguez-Berriguete

    Published 2024-07-01
    “…Using a literature-based approach, we identified 42 radiosensitising drugs with varied non-cancer indications and mechanisms of action, that have entered or completed clinical trials in combination with RT or with chemoradiotherapy. …”
    Get full text
    Article
  7. 2047

    Structural insights into antibody-based immunotherapy for hepatocellular carcinoma by Masaud Shah, Muhammad Hussain, Hyun Goo Woo

    Published 2025-01-01
    “…Several therapeutic antibodies that counter the immunosuppressive tumor microenvironment have demonstrated efficacy in clinical trials, leading to FDA approvals for advanced HCC treatment. …”
    Get full text
    Article
  8. 2048

    Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros by Konstantinos Makrilakis, Stavros Liatis

    Published 2017-01-01
    “…In nearly all asymptomatic PWD, however, the results of screening will generally not change medical therapy, since aggressive preventive measures, such as control of blood pressure and lipids, would have been already indicated, and above all, invasive revascularization procedures (either with percutaneous coronary intervention or coronary artery bypass grafting) have not been shown in randomized clinical trials to confer any benefit on morbidity and mortality. …”
    Get full text
    Article
  9. 2049

    Efficacy and Safety of Topical Timolol Eye Drops in the Treatment of Myopic Regression after Laser In Situ Keratomileusis: A Systematic Review and Meta-Analysis by Xiaochen Wang, Guiqiu Zhao, Jing Lin, Nan Jiang, Qian Wang, Qiang Xu

    Published 2015-01-01
    “…Results. We included six clinical trials involving 483 eyes in this review, including 246 eyes in treated group and 237 eyes in controlled group. …”
    Get full text
    Article
  10. 2050

    Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases by Leilei Chen, Qingqing Shen, Yingjuan Liu, Yunqi Zhang, Liping Sun, Xizhen Ma, Ning Song, Junxia Xie

    Published 2025-02-01
    “…Additionally, the promising results and limitations observed in clinical trials of these metal ion chelators will also be addressed. …”
    Get full text
    Article
  11. 2051

    Para-Phenylenediamine Induces Apoptotic Death of Melanoma Cells and Reduces Melanoma Tumour Growth in Mice by Debajit Bhowmick, Kaushik Bhar, Sanjaya K. Mallick, Subhadip Das, Nabanita Chatterjee, Tuhin Subhra Sarkar, Rajarshi Chakrabarti, Krishna Das Saha, Anirban Siddhanta

    Published 2016-01-01
    “…Despite a huge number of clinical trials, any success to find a chemotherapeutic agent that can effectively destroy melanoma is yet to be achieved. …”
    Get full text
    Article
  12. 2052

    Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury by Pascal Rowart, Pauline Erpicum, Olivier Detry, Laurent Weekers, Céline Grégoire, Chantal Lechanteur, Alexandra Briquet, Yves Beguin, Jean-Marie Krzesinski, François Jouret

    Published 2015-01-01
    “…MSC have demonstrated immunomodulatory, anti-inflammatory, and tissue repair properties in rodent studies and in preliminary clinical trials, which may open novel avenues in the management of IRI and SOT.…”
    Get full text
    Article
  13. 2053

    Acute Liver Failure Caused by Amanita phalloides Poisoning by Luca Santi, Caterina Maggioli, Marianna Mastroroberto, Manuel Tufoni, Lucia Napoli, Paolo Caraceni

    Published 2012-01-01
    “…The clinical efficacy of any modality of treatment is difficult to demonstrate since randomized, controlled clinical trials have not been reported. The use of extracorporeal liver assist devices as well as auxiliary liver transplantation may represent additional therapeutic options.…”
    Get full text
    Article
  14. 2054

    GLP-1 Receptor Agonists’ Impact on Fertility - A Review by Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec, Silvia Ciraolo, Agnieszka Kulczycka-Rowicka

    Published 2025-02-01
    “…Research Materials and Methods: The study is built upon an analysis of current literature, clinical trials, meta-analyses, and systematic reviews as well as press reports from various sources. …”
    Get full text
    Article
  15. 2055

    Remimazolam for procedural sedation in gastrointestinal endoscopy: real-life, single center observational study by Conigliaro Rita, Pigò Flavia, Caiazzo Anna, Grande Giuseppe, Russo Salvatore, Cocca Silvia, Lupo Marinella, Marocchi Margherita, Marsico Maria, Sculli Simone, Bertani Helga

    Published 2025-01-01
    “…Abstract Background and aim Remimazolam has proved to be a very promising sedative drug in randomized clinical trials for usage in a wide spectrum of patients, including critically ill ones. …”
    Get full text
    Article
  16. 2056

    Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation by Sylvie Hermouet, Edith Bigot-Corbel, Betty Gardie

    Published 2015-01-01
    “…Moreover, the JAK inhibitor clinical trials showed that the reduction of symptoms linked to inflammation was beneficial to patients even in the absence of significant decrease in the JAK2-V617F mutant load. …”
    Get full text
    Article
  17. 2057

    Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Le... by Hammoudeh AJ, Aldalal’ah M, Smadi EA, Alrishoud D, Alomari A, Alkhawaldeh M, Rizik A, Okour MF, Araydah M

    Published 2025-02-01
    “…SMuRF-less patients were younger, had less comorbid disease, received less secondary prevention pharmacotherapy and had higher rate of one year mortality than those with SMuRFs.Clinical Trials: The study is registered with ClinicalTrials.gov, unique identifier number NCT06199869.Keywords: atherosclerotic cardiovascular disease, standard modifiable risk factors, SMuRF-less patients, Middle Eastern patients…”
    Get full text
    Article
  18. 2058
  19. 2059
  20. 2060

    Diagnostic accuracy of calculated serum osmolarity to predict dehydration in older people: adding value to pathology laboratory reports by Lee Shepstone, John F Potter, Lee Hooper, Asmaa Abdelhamid, Amy Jennings, Paul R Hunter, W Garry John, Neil P Walsh, Adam Ali, Diane K Bunn, Susan Kerry, Gregor Lindner, Carmen A Pfortmueller, Fredrik Sjöstrand, Susan J Fairweather-Tait

    Published 2015-10-01
    “…Given costs and prevalence of dehydration in older people we suggest use of the best formula by pathology laboratories using a cutpoint of 295 mOsm/L (sensitivity 85%, specificity 59%), to report dehydration risk opportunistically when serum glucose, urea and electrolytes are measured for other reasons in older adults.Trial registration numbers: DRIE: Research Register for Social Care, 122273; NU-AGE: ClinicalTrials.gov NCT01754012.…”
    Get full text
    Article